IL17A and inflammatory bowel disease: We aimed to assess differences in safety signals using the FDA Adverse Event Reporting System (FAERS) database, and describe characteristics, management, and prognosis of IBD flare or new onset in patients after anti-IL-17 drug therapy in a real-life setting, which provides valuable information about emerging gastrointestinal safety issues related to IL-17 inhibitors.